{"id":11701,"date":"2019-01-25T12:11:50","date_gmt":"2019-01-25T17:11:50","guid":{"rendered":"https:\/\/camrt.wpenginepowered.com\/fr\/?p=11701"},"modified":"2025-09-05T10:50:14","modified_gmt":"2025-09-05T14:50:14","slug":"lutathera-lutetium-177lu-oxodotreotide-approuve-au-canada","status":"publish","type":"post","link":"https:\/\/camrt.ca\/fr\/blog\/2019\/01\/25\/lutathera-lutetium-177lu-oxodotreotide-approuve-au-canada\/","title":{"rendered":"LUTATHERA\u00ae (lutetium (177Lu) oxodotreotide) approuv\u00e9 au Canada"},"content":{"rendered":"<p>Bill Dickie, pr\u00e9sident et chef de la direction de Advanced Accelerator Applications (AAA) Canada Inc., a d\u00e9clar\u00e9 ce qui suit\u00a0:<\/p>\n<p><em>\u00ab\u00a0En tant que premier agent de th\u00e9rapie radionucl\u00e9ide du r\u00e9cepteur du peptide (PRRT) approuv\u00e9 au Canada, Lutathera repr\u00e9sente une innovation importante pour la communaut\u00e9 des tumeurs neuroendocrinienne. Nous sommes fiers de travailler avec les agences du gouvernement f\u00e9d\u00e9ral et des provinces pour rendre cette importante option de traitement \u00e0 la disposition des patients qui ont besoin de cette th\u00e9rapie.<\/em><\/p>\n<p><em>Nous croyons que la m\u00e9decine nucl\u00e9aire a le potentiel d\u2019offrir de nombreux avantages pour les patients atteints d\u2019un cancer et esp\u00e9rons apporter d\u2019autres progr\u00e8s comme Lutathera au Canada dans le futur. L\u2019approbation de th\u00e9rapies comme Lutathera contribue \u00e0 mettre en lumi\u00e8re le r\u00f4le des technologues en radiation m\u00e9dicale dans les soins aux patients.\u00a0\u00bb<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bill Dickie, pr\u00e9sident et chef de la direction de Advanced Accelerator Applications (AAA) Canada Inc., a d\u00e9clar\u00e9 ce qui suit\u00a0: \u00ab\u00a0En tant que premier agent de th\u00e9rapie radionucl\u00e9ide du r\u00e9cepteur du peptide (PRRT) approuv\u00e9 au Canada, Lutathera repr\u00e9sente une innovation importante pour la communaut\u00e9 des tumeurs neuroendocrinienne. Nous sommes fiers de travailler avec les agences [&hellip;]<\/p>\n","protected":false},"author":30,"featured_media":11695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[104],"tags":[],"class_list":["post-11701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/posts\/11701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/comments?post=11701"}],"version-history":[{"count":0,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/posts\/11701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/media\/11695"}],"wp:attachment":[{"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/media?parent=11701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/categories?post=11701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/camrt.ca\/fr\/wp-json\/wp\/v2\/tags?post=11701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}